BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today […]
BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
Leadership investment supports expanded hospital commercial push PR Audio: POMPANO BEACH, Fla., October 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced its […]
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company’s sterile placental allograft, micronized wound care, and umbilical cord extract technologies PR Audio: POMPANO BEACH, Fla., October 1, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the […]
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
POMPANO BEACH, Fla., September 30, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance […]
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
PR Audio: PR Video Overview: POMPANO BEACH, Fla., September 18, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a […]
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
Additions extend BioStem’s hospital channel to its BioRetain® wound care line PR Audio: POMPANO BEACH, Fla., September 4, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft […]
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
POMPANO BEACH, Fla., Sept. 03, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the H.C. Wainwright 28th Annual Global Investment […]
BioStem Technologies to Present at the Sidoti MicroCap Conference
POMPANO BEACH, Fla., August 14, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Sidoti MicroCap Virtual […]
BioStem Technologies Reports Second Quarter 2026 Financial Results
Generates 29% sequential revenue growth, increasing to $7.9 million;Raises full-year 2026 revenue guidanceUplists to Nasdaq Capital Market PR Audio: POMPANO BEACH, FL, August 12, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (Nasdaq: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue […]
BioStem Technologies Announces Nasdaq Uplisting
Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., August 6, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq […]